Trial to Compare the Routes of Administration of an Investigational, Personalized, Therapeutic Cancer Vaccine Oncophage (HSPPC-96) in Patients With Metastatic Renal Cell Carcinoma

Inclusion Criteria: * Suspected metastatic renal cell carcinoma (AJCC Stage IV) with intact primary tumor * No previous therapy for metastatic renal cell carcinoma * Measurable disease (RECIST criteria) * Primary tumor greater than or equal to 7cm on CT or MRI * ECOG performance status 0-1 * At least 18 years old * Life expectancy \> 3 months * Adequate cardiac function (NYHA I-II) * Not pregnant * Provide written informed consent * Absence of multiple liver metastases, brain or threatening bone metastases (axial skeleton and/or pathological features) * Planned complete nephrectomy Exclusion Criteria: * History of primary or secondary immunodeficiency, or patients using systemic corticosteroids or cyclosporin A * Other cancer (including renal cell carcinoma) within the last five years (with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri or basal or squamous cell carcinoma of the skin) * Embolization of the renal artery prior to nephrectomy * Active, uncontrolled infection or other serious medical illnesses, preventing study completion, in the opinion of the Principal Investigator